The company currently has 10 manufacturing facilities in India, the US and Canada with 6,200 as global headcount.

JLL received a warning letter from the USFDA over violation of manufacturing norms at one of its plants located in Washington state.

Jubilant Life Sciences was witnessing selling pressure after one of its manufacturing facilities in the US, was issued a warning letter (WL...

Shares of Jubilant Life Sciences fell 5 per cent after the US health regulator issued a warning letter for violation of manufacturing norms...

Jubilant Life Sciences today said it has secured contracts worth more than $90 million (over Rs 440 crore) from four life sciences firms.

The company's American subsidiary, Jubilant HollisterStier, has begun production of the drug at its Montreal facility.

Jubilant Life Sciences today said its has signed a contract manufacturing agreement with an undisclosed US pharmaceutical firm to produce a...

The acquisition of Canada-based Draxis Health is expected to enhance Jubilant Organosys’ presence in the regulated markets of North America...

This is the Delhi company's sixth buy and its first in Canada. Last year, it acquired Hollister Stier in the US for $125 million.

Jubilant Organosys is evaluating various proposals to acquire companies in the contract research and manufacturing services (CRAMS), drug d...

The acquisition will augment the Indian firm's grip on custom research & manufacturing service biz globally.

Jubilant Organosys is acquiring US-based contract research and manufacturing services (CRAMS) company Hollister-Stier Labora-tories LLC for...